In vitro EAS-mediated activity of Alternaria toxins
Authors:
- Eliana SpiliotiESEliana Spilioti
- Anastasia SpyropoulouASAnastasia Spyropoulou
- Laurent GatéLGLaurent Gaté
- Mylène LorcinMLMylène Lorcin
- Kyriaki MacheraKMKyriaki Machera
- Alexandra NestoraANAlexandra Nestora
- Anastasia RepouskouARAnastasia Repouskou
- Ioannis TheologidisITIoannis Theologidis
- Doris MarcoDoris Marco
- Anne-Cathrin BehrABAnne-Cathrin Behr
Preprint
Abstract
Alternaria mycotoxins represent an emerging concern due to their frequent occurrence in food and feed. However, available toxicological data remain limited. Under the current EU regulatory framework, and in line with the EFSA/ECHA/JRC guidance for the identification of endocrine disruptors (EDs), assessment of endocrine activity relies on standardized assays performed according to OECD Test Guidelines (TGs) for the estrogen-, androgen- and steroidogenesis- (EAS) modalities. Within the framework of the European Partnership for the Assessment of Risks from Chemicals (PARC), standardized in vitro methods of regulatory relevance were performed for six chemically characterized Alternaria toxins, aiming to address current regulatory gaps on EAS-mediated activity. Alternariol (AOH), alternariol monomethyl ether (AME), tenuazonic acid (TeA), altertoxin-I (ATX-I), tentoxin (TEN) and altenuene (ALT) were assessed over a broad concentration range, from 0.001 up to 60 μM, depending on cytotoxicity and solubility profile of each compound. Our findings indicate estrogenic activity for AOH (PC 50 : 3.9 - 4.6 µM) and AME (PC 50 : 5.2 - 8.5 µM) in the estrogen receptor transactivation assay (OECD TG 455), as well as an anti-estrogenic activity for ATX-I (IC 30 : 0.27 - 0.37 µM). Minimal positive responses were observed at high concentrations for AOH (from the dose of 3 µM) and for AME (from the dose of 10 µM) in the agonistic part of the androgen receptor transactivation assay (OECD TG 458), which may also reflect glucocorticoid receptor activation. No effects on estradiol or testosterone production were observed for any of the tested Alternaria compounds in the steroidogenesis assay (OECD TG 456).Keywords
This publication has 31 references indexed in Scilit:
- Discovery of the Alternaria mycotoxins alterperylenol and altertoxin I as novel immunosuppressive and antiestrogenic compounds in vitroArchives of Toxicology, 2024
- Hazard characterization of Alternaria toxins to identify data gaps and improve risk assessment for human healthArchives of Toxicology, 2023
- Alternaria toxins as casein kinase 2 inhibitors and possible consequences for estrogenicity: a hybrid in silico/in vitro studyArchives of Toxicology, 2020
- Naturally occurring mixtures of Alternaria toxins: anti-estrogenic and genotoxic effects in vitroArchives of Toxicology, 2019
- An integrated in silico/in vitro approach to assess the xenoestrogenic potential of Alternaria mycotoxins and metabolitesFood Chemistry, 2018
- Nonsteroidal mycotoxin alternariol is a full androgen agonist in the yeast reporter androgen bioassayEnvironmental Toxicology and Pharmacology, 2017
- Endocrine activity of mycotoxins and mycotoxin mixturesFood and Chemical Toxicology, 2016
- Using SILAC proteomics to investigate the effect of the mycotoxin, alternariol, in the human H295R steroidogenesis modelCell Biology and Toxicology, 2014
- An in vitro investigation of endocrine disrupting effects of the mycotoxin alternariolToxicology and Applied Pharmacology, 2013
- Estrogenic and clastogenic potential of the mycotoxin alternariol in cultured mammalian cellsFood and Chemical Toxicology, 2006